Subscribe To
4d molecular therapeutics, inc. (fdmt) soars 11.2%: is further upside left in the stock?
4D molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average tr...
April 14, 2023, 6:08 am
molecular partners to present additional preclinical data supporting the company’s radio darpin therapy platform at aacr
Targeted radionuclide delivery platform strengthened by new safety and mechanistic data Data includes review of high tumor penetration potential of DA...
April 14, 2023, 5:00 am
molecular partners to present additional preclinical data supporting the company's radio darpin therapy platform at aacr
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- molecular Partners...
April 14, 2023, 1:00 am
Gain therapeutics appoints c. evan ballantyne as chief financial officer
BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company ...
April 12, 2023, 8:30 pm
Kalvista pharmaceuticals to present at 22nd annual needham virtual healthcare conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical compa...
April 12, 2023, 6:30 am
Thermo fisher (tmo) expands to boost commercial manufacturing
Thermo Fisher's expansion in Bourgoin is built on the company's investments in small molecule solutions...
April 11, 2023, 1:48 pm
Sutro: too little, too late for stro-002, but platform is interesting
STRO is playing second fiddle to perpetually second fiddle player ImmunoGen in ovarian cancer. Although there are certain positive aspects to the
April 11, 2023, 1:17 pm
Kymera therapeutics to report first quarter 2023 financial results on may 4
WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing ta...
April 11, 2023, 7:00 am
molecular templates, inc. reports fourth quarter 2022 financial results and business update
Announces strategic reprioritization to focus on clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to BMS coll...
March 30, 2023, 10:10 pm
molecular templates inc. (mtem) reports q4 loss, lags revenue estimates
molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respective...
March 30, 2023, 9:40 pm
molekule reports fourth quarter and full year 2022 financial results
Introduces Q1 2023 Revenue Guidance of Approximately $8 Million and Full Year Fiscal 2023 Revenue Guidance of Between $60-$70 Million PALM BEACH GARDE...
March 30, 2023, 8:15 pm
Rapt therapeutics: potential strong upside ahead
RAPT Therapeutics, Inc. is a clinical-stage biotech developer of specific small molecules that can modu...
March 30, 2023, 12:12 am
Alpine immune: rebuilding itself from scratch, but long way to go before proof
Last year, ALPN ditched its lead program after a second patient death in a CD28 molecule, a previously ...
March 29, 2023, 7:37 am
moleculin biotech, inc. (mbrx) upgraded to buy: what does it mean for the stock?
moleculin Biotech, Inc. (MBRX) might move higher on growing optimism about its earnings prospects, whic...
March 27, 2023, 1:45 pm
4d molecular therapeutics: promising preliminary safety and efficacy for 4d-310
With its strong focus on product design and development excellence, as evidenced by its sustained success in IND clearance, 4D ...
March 25, 2023, 1:38 am
Biocept says enrollment begins in foresee clinical trial using cnside to evaluate patients with leptomeningeal metastases
Biocept Inc (NASDAQ:BIOC), a provider of molecular diagnostic assays, products and services, revealed t...
March 24, 2023, 9:01 am
Nautilus biotechnology to participate in b. riley securities' disruptive biotech enabling technologies – proteomics, virtual conference
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-...
March 23, 2023, 8:00 am
Gilead (gild) exercises option to license nurix's candidate
Gilead (GILD) exercises an option under its collaboration agreement with Nurix to license the latter???s investigational targeted protein degrader
March 21, 2023, 4:01 pm
Nurix's (nrix) stock up due to license option exercise by gilead
Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational t...
March 21, 2023, 11:28 am
Terns pharmaceuticals: early-stage biopharma worthy of your attention
TERN has a growing pipeline of early-stage assets against validated targets. TERN's internal discovery team has been productive at developing small ...
March 21, 2023, 8:13 am